Head-To-Head Survey: Precipio (NASDAQ:PRPO) and P3 Health Partners (NASDAQ:PIII)

Precipio (NASDAQ:PRPO) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings & Valuation

This table compares Precipio and P3 Health Partners”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05 million	2.13	-$360,000.00	($0.25)	-114.72
P3 Health Partners	$1.46 billion	0.01	-$147.95 million	($45.20)	-0.06

Precipio has higher earnings, but lower revenue than P3 Health Partners. Precipio is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Precipio has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Precipio and P3 Health Partners, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1	0	0	0	1.00
P3 Health Partners	1	2	1	0	2.00

P3 Health Partners has a consensus price target of $3.50, indicating a potential upside of 39.78%. Given P3 Health Partners’ stronger consensus rating and higher possible upside, analysts clearly believe P3 Health Partners is more favorable than Precipio.

Insider and Institutional Ownership

10.4% of Precipio shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 16.9% of Precipio shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Precipio and P3 Health Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precipio	-1.51%	-2.78%	-1.84%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Summary

Precipio beats P3 Health Partners on 8 of the 14 factors compared between the two stocks.

About Precipio

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.